AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.
You may also be interested in...
Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.
The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.